The history of the erectile dysfunction drug presents a complex picture for shareholders. While the initial introduction generated substantial returns, the lapse of its patent opened the floodgates to cheaper https://bookmarketmaven.com/story22512462/sildenafil-and-big-pharma-a-precarious-opportunity